Analyst Ratings for Gossamer Bio
Over the past 3 months, 5 analysts have published their opinion on Gossamer Bio (NASDAQ:GOSS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Raymond James Maintains Outperform on Gossamer Bio, Raises Price Target to $14
Raymond James analyst Steven Seedhouse maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $10 to $14.
Twitter, Delta Air Lines And 45 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 122.4% to $6.76. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
SVB Leerink Maintains Outperform on Gossamer Bio, Lowers Price Target to $15
SVB Leerink analyst Joseph Schwartz maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $16 to $15.